Novoste Corporation
Results find vascular brachytherapy effective treatment for in-stent restenosis
Published in Cardiovascular Business Week, November 15th, 2005
Novoste Corporation (NOVT) announced the results of its post approval studies (PAS), which included the 3-, 4-, and 5-year follow-up of the "Stents and Radiation Therapy" (StarT) and "Stents And Radiation Therapy 40" (StarT 40/20) trials, which further demonstrated that routine application of vascular brachytherapy (VBT) is effective in the treatment of in-stent restenosis beyond the earlier reported 2-year follow-up.
The post-approval studies were intended to evaluate the long-term safety and efficacy of the Beta-Cath System in patients who were enrolled in the StarT and StarT 40/20 trials for the treatment of in-stent restenosis of native coronary arteries beyond the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Cardiogenesis Corp.
Cardiology medical device company reports 55% increase in revenue - Cardium Therapeutics, Inc.
Cardiology company merges with Aries Ventures - GenVec, Inc.
Gene-based company announces plan to sell myoblast cell therapy program - Medicure Inc.
Cardiovascular-focused drug discovery company reports Q1 2006 financial results - Trigen Holdings AG
Cardiovascular drug discovery company completes $31.9 million financing round - Vasomedical, Inc.
Cardiovascular disease-focused company reports revenues of $3.5 million in Q1 2006 - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
